---
title: "Mapping polygenic risk scores to brain cell types in neurodegenerative diseases"
id: "medrxiv-12-mapping-polygenic-risk-scores-to-brain-cells-insights-for-neurodegenerative"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-mapping-polygenic-risk-scores-to-brain-cells-insights-for-neurodegenerative"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.08.26365054v1?rss=1"
published_at: "2026-10-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Mapping polygenic risk scores to brain cell types in neurodegenerative diseases
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-mapping-polygenic-risk-scores-to-brain-cells-insights-for-neurodegenerative
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.08.26365054v1?rss=1)
- **Published At:** 2026-10-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors analysed multiple neurodegenerative diseases (NDDs) using **polygenic risk scores (PRSs)** constructed from UK Biobank data and restricted to genes reported as expressed in major brain cell types: microglia, astrocytes, oligodendrocytes and neurons. - There was substantial overlap among the cell-type specific gene sets (approximately **21–29%** shared), and genes at the **APOE** locus or neighbouring APOE genes were present across all cell-type gene sets, indicating shared genetic variation captured by current annotations. - When considered jointly, cell-type specific PRSs accounted for a large fraction (**60–93%**) of genetic liability for NDDs in which dementia is a major clinical feature. - **Alzheimer's disease (AD)** showed associations across all cell types; oligodendrocyte- and astrocyte-based PRSs had strong effects that were independent of **APOE**. - AD PRS and APOE status independently distinguished Parkinson's disease (PD) with dementia from PD without dementia, indicating overlapping but distinct genetic influences on dementia across disorders. - Parkinson's disease without dementia and amyotrophic lateral sclerosis (ALS) displayed more distinct genetic profiles with limited overlap with other NDDs. - The findings highlight both shared and disease-specific genetic contributions across NDDs and emphasize limitations: imperfect alignment between clinical phenotype and underlying pathology, and extensive overlap of gene expression across brain cell types that complicate attribution of risk to single cell types. - Data access and transparency: analyses used UK Biobank under application 109607; all PRSs and SNP lists will be returned to UK Biobank and made available to other researchers. - Ethical and reporting statements were provided by the authors; no competing interests were declared.
## Clinical Analysis & Structured Key Points
Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases | medRxiv Skip to main content Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases Emily Simmonds , Anna McKeever , Ümran Yaman , Ganna Leonenko , Kerbez Kimatova , View ORCID Profile Philip Taylor , Siddharthan Chandran , Mina Ryten , Baljit Khakh , View ORCID Profile John T O'Brien , View ORCID Profile Tara Spires-Jones , View ORCID Profile Dervis A Salih , View ORCID Profile Valentina Escott-Price doi: https://doi.org/10.64898/2026.10.08.26365054 Emily Simmonds 1 Cardiff University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anna McKeever 2 Cambridge University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ümran Yaman 3 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ganna Leonenko 1 Cardiff University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kerbez Kimatova 1 Cardiff University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Philip Taylor 1 Cardiff University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Philip Taylor Siddharthan Chandran 4 University of Edinburgh Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mina Ryten 2 Cambridge University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Baljit Khakh 1 Cardiff University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site John T O'Brien 2 Cambridge University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for John T O'Brien Tara Spires-Jones 4 University of Edinburgh Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tara Spires-Jones Dervis A Salih 3 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Dervis A Salih Valentina Escott-Price 1 Cardiff University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Valentina Escott-Price For correspondence: escottpricev{at}cardiff.ac.uk Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Neurodegenerative diseases (NDDs) are driven by multiple related yet distinct pathological processes that evolve over decades, resulting in substantial clinical and neuropathological heterogeneity. Postmortem examinations of older individuals frequently reveal multiple coexisting neuropathologies, however, the underlying pathological processes cannot be easily assessed directly in living individuals. To quantify pathology-specific genetic signatures, we analysed a spectrum of NDDs using polygenic risk scores (PRSs) in the UK Biobank, restricting analyses to genes reported to be expressed in major brain cell-types, including microglia, astrocytes, oligodendrocytes, and neurons. We found substantial overlap among purportedly cell-type specific gene sets (21-29%), with APOE or neighbouring genes from the APOE locus represented in all gene sets, indicating that current cell-type specific annotations capture considerable shared genetic variation across cell-types. Jointly, cell-type specific PRSs explained a large proportion (60-93%) of the genetic liability for NDDs in which dementia is a major clinical manifestation. Alzheimer's disease (AD) showed associations across all cell-types, with oligodendrocyte- and astrocyte-based PRSs demonstrating strong effects independent of APOE. AD PRS and APOE status independently differentiated Parkinson's disease (PD) with dementia from PD without dementia. PD without dementia and amyotrophic lateral sclerosis (ALS) exhibited distinct genetic profiles, with limited overlap with other NDDs. Collectively, these findings reveal both shared and disease-specific genetic contributions across neurodegenerative disorders and demonstrate that currently available cell-type specific gene sets capture substantial overlapping genetic risk. The imperfect alignment between clinical phenotypes and underlying pathology, coupled with the extensive overlap of gene expression across these cell types, underscores the persistent challenges in resolving the genetic architecture of neurodegenerative diseases and elucidating their underlying biological mechanisms. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Access to UK Biobank data can be requested from https://www.ukbiobank.ac.uk/use-our-data/apply-for-access/. All polygenic risk scores, whole genome and cell type specific, and SNP lists for each cell type will be returned to UK Biobank and made available to other researchers using UK Biobank. UKB access was under application number 109607. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Access to UK Biobank data can be requested from https://www.ukbiobank.ac.uk/use-our-data/apply-for-access/. All polygenic risk scores, whole genome and cell type specific, and SNP lists for each cell type will be returned to UK Biobank and made available to other researchers using UK Biobank. https://www.ukbiobank.ac.uk/use-our-data/apply-for-access/ Funder Information Declared UK Dementia Research Institute , UKDRI-3206 Medical Research Council , MR/T04604X/1 , MR/L023784/2 , MR/L010305/1 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted October 11, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases Emily Simmonds , Anna McKeever , Ümran Yaman , Ganna Leonenko , Kerbez Kimatova , Philip Taylor , Siddharthan Chandran , Mina Ryten , Baljit Khakh , John T O'Brien , Tara Spires-Jones , Dervis A Salih , Valentina Escott-Price medRxiv 2026.10.08.26365054; doi: https://doi.org/10.64898/2026.10.08.26365054 Share This Article: Copy Citation Tools Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases Emily Simmonds , Anna McKeever , Ümran Yaman , Ganna Leonenko , Kerbez Kimatova , Philip Taylor , Siddharthan Chandran , Mina Ryten , Baljit Khakh , John T O'Brien , Tara Spires-Jones , Dervis A Salih , Valentina Escott-Price medRxiv 2026.10.08.26365054; doi: https://doi.org/10.64898/2026.10.08.26365054 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Genetic and Genomic Medicine Subject Areas All Articles Addiction Medicine (626) Allergy and Immunology (914) Anesthesia (341) Cardiovascular Medicine (4897) Dentistry and Oral Medicine (487) Dermatology (421) Emergency Medicine (664) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1652) Epidemiology (16099) Forensic Medicine (35) Gastroenterology (1221) Genetic and Genomic Medicine (7148) Geriatric Medicine (740) Health Economics (1078) Health Informatics (5159) Health Policy (1450) Health Systems and Quality Improvement (1801) Hematology (594) HIV/AIDS (1361) Infectious Diseases (except HIV/AIDS) (16384) Intensive Care and Critical Care Medicine (1186) Medical Education (682) Medical Ethics (156) Nephrology (731) Neurology (7423) Nursing (372) Nutrition (1105) Obstetrics and Gynecology (1270) Occupational and Environmental Health (1015) Oncology (3671) Ophthalmology (1073) Orthopedics (399) Otolaryngology (460) Pain Medicine (486) Palliative Medicine (142) Pathology (713) Pediatrics (1828) Pharmacology and Therapeutics (742) Primary Care Research (779) Psychiatry and Clinical Psychology (6014) Public and Global Health (9865) Radiology and Imaging (2471) Rehabilitation Medicine and Physical Therapy (1487) Respiratory Medicine (1257) Rheumatology (653) Sexual and Reproductive Health (789) Sports Medicine (590) Surgery (789) Toxicology (108) Transplantation (312) Urology (299)
## Related Clinical Research

- [Sensorimotor cortex beta activity during cued gait differs in Parkinson’s freezers and non-freezers](https://medichelpline.com/clinical-feed/medrxiv-2-sensorimotor-cortex-activity-during-cued-gait-differs-in-parkinson-s-freezers.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Pre-diagnostic 1-year prevalence of polypharmacy and PIMcog in Norwegian outpatients with MCI or d](https://medichelpline.com/clinical-feed/plos-one-14-one-year-pre-diagnostic-prevalence-and-associated-factors-of-polypharmacy-and.md)
- [Orexin agonist ALKS 7290 shows ADHD symptom improvement in early Phase 1 trial](https://medichelpline.com/clinical-feed/stat-news-0-stat-alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.